Miguel Perales MD
@drmiguelperales.bsky.social
Chief Adult BMT MSKCC | Past-President ASTCT | Board Member NMDP | Chair Committee Transplant/Cell Ther ALLIANCE | Immigrant 🇪🇸🇬🇧 #MedSky Opinions mine/not MSK
https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
Pinned
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...
F.D.A. Names Agency Veteran to Run Drug Division
www.nytimes.com
November 12, 2025 at 12:24 PM
F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...
Reposted by Miguel Perales MD
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
Artificial intelligence in hematology
In the last 2 years, the capabilities of artificial intelligence (AI) have progressed rapidly and are increasingly being integrated into hematology practic
ashpublications.org
November 6, 2025 at 10:55 PM
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
Hopefully on my way to Alliance meeting in Chicago- look forward to Transplant and Cellular Based Therapies Committee tomorrow
November 6, 2025 at 9:15 PM
Hopefully on my way to Alliance meeting in Chicago- look forward to Transplant and Cellular Based Therapies Committee tomorrow
Reposted by Miguel Perales MD
A team at MSK is shedding new light on #VEXAS syndrome, a severe autoinflammatory condition arising from a mutation in the UBA1 gene.
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
November 6, 2025 at 6:39 PM
A team at MSK is shedding new light on #VEXAS syndrome, a severe autoinflammatory condition arising from a mutation in the UBA1 gene.
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.
bit.ly/4oRQ5LF
‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say www.nytimes.com/2025/11/01/u...
‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say
www.nytimes.com
November 1, 2025 at 11:35 PM
‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say www.nytimes.com/2025/11/01/u...
Great meeting with friends and colleagues to discuss chronic GVHD last week in Detroit with Steven Pavletic, Daniel Couriel, Corey Cutler, Stephanie Lee & Stefanie Sarantopoulos
October 25, 2025 at 3:44 PM
Great meeting with friends and colleagues to discuss chronic GVHD last week in Detroit with Steven Pavletic, Daniel Couriel, Corey Cutler, Stephanie Lee & Stefanie Sarantopoulos
Reposted by Miguel Perales MD
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:
ESMO 2025 Research Roundup: MSK Presents Exciting Advances in Medical Oncology Research
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative...
www.mskcc.org
October 20, 2025 at 6:07 PM
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:
Reposted by Miguel Perales MD
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
October 18, 2025 at 5:02 PM
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
Reposted by Miguel Perales MD
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
October 18, 2025 at 12:57 PM
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
Reposted by Miguel Perales MD
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
October 18, 2025 at 3:02 PM
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
Reposted by Miguel Perales MD
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
October 17, 2025 at 5:03 PM
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
Reposted by Miguel Perales MD
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
October 10, 2025 at 9:37 AM
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
Reposted by Miguel Perales MD
Since 2012, the ASH Bridge Grant has funded 205 researchers with $28M, leading to $680M in follow-on NIH funding. These grants keep labs running and fuel breakthroughs in hematology. Learn more: https://bit.ly/48yINrB
October 10, 2025 at 8:01 PM
Since 2012, the ASH Bridge Grant has funded 205 researchers with $28M, leading to $680M in follow-on NIH funding. These grants keep labs running and fuel breakthroughs in hematology. Learn more: https://bit.ly/48yINrB
Reposted by Miguel Perales MD
At 7 years old, Emily became the first child in the world to receive CAR T-cell therapy. After three relapses and being sent to hospice, Emily got a second chance at life with this treatment. Help protect access to life-saving treatments: https://ow.ly/rXY150X5Tso
#Fight4Hematology #HemeSky
#Fight4Hematology #HemeSky
October 10, 2025 at 2:01 PM
At 7 years old, Emily became the first child in the world to receive CAR T-cell therapy. After three relapses and being sent to hospice, Emily got a second chance at life with this treatment. Help protect access to life-saving treatments: https://ow.ly/rXY150X5Tso
#Fight4Hematology #HemeSky
#Fight4Hematology #HemeSky
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
October 10, 2025 at 9:37 AM
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
Reposted by Miguel Perales MD
October 9, 2025 at 10:21 AM
Reposted by Miguel Perales MD
Un merecido reconocimiento al @drmiguelperales.bsky.social por su larga trayectoria.
Siempre dispuesto a compartir conocimientos y procurar que los residentes de España puedan visitar @mskcancercenter.bsky.social. Para mi una de las mejores experiencias de mi residencia.
👏Muchas felicidades👏
Siempre dispuesto a compartir conocimientos y procurar que los residentes de España puedan visitar @mskcancercenter.bsky.social. Para mi una de las mejores experiencias de mi residencia.
👏Muchas felicidades👏
October 9, 2025 at 11:30 AM
Un merecido reconocimiento al @drmiguelperales.bsky.social por su larga trayectoria.
Siempre dispuesto a compartir conocimientos y procurar que los residentes de España puedan visitar @mskcancercenter.bsky.social. Para mi una de las mejores experiencias de mi residencia.
👏Muchas felicidades👏
Siempre dispuesto a compartir conocimientos y procurar que los residentes de España puedan visitar @mskcancercenter.bsky.social. Para mi una de las mejores experiencias de mi residencia.
👏Muchas felicidades👏
Reposted by Miguel Perales MD
🎙️New Podcast Episode!
Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA
Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA
October 6, 2025 at 7:45 AM
🎙️New Podcast Episode!
Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA
Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA
Great session on cGVHD at #COSTEM2025 in Berlin last week. Got to debate Dr. Francesca Kinsella
October 4, 2025 at 5:22 PM
Great session on cGVHD at #COSTEM2025 in Berlin last week. Got to debate Dr. Francesca Kinsella
Go see Art on Broadway. Great show!
October 4, 2025 at 12:42 PM
Go see Art on Broadway. Great show!
Reposted by Miguel Perales MD
BMT InfoNet invites your patients to a free live webinar with leading CAR T-cell therapy experts.
Encourage your patients and caregivers to register and submit their questions in advance!
🗓 Tuesday, October 21
🕖 7:00 PM ET
🔗 bmtinfonet.org/event/ask-ca...
Encourage your patients and caregivers to register and submit their questions in advance!
🗓 Tuesday, October 21
🕖 7:00 PM ET
🔗 bmtinfonet.org/event/ask-ca...
October 1, 2025 at 11:51 PM
BMT InfoNet invites your patients to a free live webinar with leading CAR T-cell therapy experts.
Encourage your patients and caregivers to register and submit their questions in advance!
🗓 Tuesday, October 21
🕖 7:00 PM ET
🔗 bmtinfonet.org/event/ask-ca...
Encourage your patients and caregivers to register and submit their questions in advance!
🗓 Tuesday, October 21
🕖 7:00 PM ET
🔗 bmtinfonet.org/event/ask-ca...
Reposted by Miguel Perales MD
💉New study of HPV vaccine shows “robust population-level effectiveness & herd protection in adolescent girls & young women”
From 2006-2023:
➡️ Proportion of vaxxed women positive for high-risk HPV-16 & -18 types fell 98.4%, proportion of unvaxxed women fell 71.6%
1/2
jamanetwork.com/journals/jam...
From 2006-2023:
➡️ Proportion of vaxxed women positive for high-risk HPV-16 & -18 types fell 98.4%, proportion of unvaxxed women fell 71.6%
1/2
jamanetwork.com/journals/jam...
Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine
This cross-sectional study investigates population-level effectiveness and herd protection in the first 17 years after human papillomavirus (HPV) vaccination among adolescent girls and young women at ...
jamanetwork.com
September 29, 2025 at 11:00 PM
💉New study of HPV vaccine shows “robust population-level effectiveness & herd protection in adolescent girls & young women”
From 2006-2023:
➡️ Proportion of vaxxed women positive for high-risk HPV-16 & -18 types fell 98.4%, proportion of unvaxxed women fell 71.6%
1/2
jamanetwork.com/journals/jam...
From 2006-2023:
➡️ Proportion of vaxxed women positive for high-risk HPV-16 & -18 types fell 98.4%, proportion of unvaxxed women fell 71.6%
1/2
jamanetwork.com/journals/jam...
Reposted by Miguel Perales MD
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. Read the full report: nej.md/48gcBZV
#MedSky #GastroSky
#MedSky #GastroSky
September 26, 2025 at 2:06 PM
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. Read the full report: nej.md/48gcBZV
#MedSky #GastroSky
#MedSky #GastroSky
Reposted by Miguel Perales MD
@bloomberg.com reports that a top advisor to RFK Jr. said they're considering adding autism symptoms to the federal vaccine court program. Read my story for @nbcnews.com on how that could bring a halt to vaccine manufacturing in the U.S.
www.nbcnews.com/health/healt...
www.nbcnews.com/health/healt...
RFK Jr. has the federal vaccine court in his sights. Attacking it could threaten vaccine production in the U.S.
The Vaccine Injury Compensation Program created a special court for vaccine-related injuries. Kennedy has called it “broken” and vows to “fix it.”
www.nbcnews.com
September 26, 2025 at 5:03 PM
@bloomberg.com reports that a top advisor to RFK Jr. said they're considering adding autism symptoms to the federal vaccine court program. Read my story for @nbcnews.com on how that could bring a halt to vaccine manufacturing in the U.S.
www.nbcnews.com/health/healt...
www.nbcnews.com/health/healt...